<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Chron Obstruct Pulmon Dis</journal-id><journal-id journal-id-type="iso-abbrev">Int J Chron Obstruct Pulmon Dis</journal-id><journal-id journal-id-type="publisher-id">International Journal of COPD</journal-id><journal-title-group><journal-title>International Journal of Chronic Obstructive Pulmonary Disease</journal-title></journal-title-group><issn pub-type="ppub">1176-9106</issn><issn pub-type="epub">1178-2005</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25114520</article-id><article-id pub-id-type="pmc">4122579</article-id><article-id pub-id-type="doi">10.2147/COPD.S65621</article-id><article-id pub-id-type="publisher-id">copd-9-805</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Pulmonary function impairment in patients with combined pulmonary fibrosis and emphysema with and without airflow obstruction</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kitaguchi</surname><given-names>Yoshiaki</given-names></name><xref ref-type="aff" rid="af1-copd-9-805">1</xref><xref ref-type="aff" rid="af2-copd-9-805">2</xref></contrib><contrib contrib-type="author"><name><surname>Fujimoto</surname><given-names>Keisaku</given-names></name><xref ref-type="aff" rid="af3-copd-9-805">3</xref><xref ref-type="corresp" rid="c1-copd-9-805"/></contrib><contrib contrib-type="author"><name><surname>Hanaoka</surname><given-names>Masayuki</given-names></name><xref ref-type="aff" rid="af1-copd-9-805">1</xref></contrib><contrib contrib-type="author"><name><surname>Honda</surname><given-names>Takayuki</given-names></name><xref ref-type="aff" rid="af4-copd-9-805">4</xref></contrib><contrib contrib-type="author"><name><surname>Hotta</surname><given-names>Junichi</given-names></name><xref ref-type="aff" rid="af2-copd-9-805">2</xref></contrib><contrib contrib-type="author"><name><surname>Hirayama</surname><given-names>Jiro</given-names></name><xref ref-type="aff" rid="af2-copd-9-805">2</xref></contrib></contrib-group><aff id="af1-copd-9-805"><label>1</label>First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan</aff><aff id="af2-copd-9-805"><label>2</label>Department of Internal Medicine, Okaya City Hospital, Okaya, Japan</aff><aff id="af3-copd-9-805"><label>3</label>Department of Clinical Laboratory Sciences, Shinshu University School of Medicine, Matsumoto, Japan</aff><aff id="af4-copd-9-805"><label>4</label>Department of Laboratory Medicine, Shinshu University School of Medicine, Matsumoto, Japan</aff><author-notes><corresp id="c1-copd-9-805">Correspondence: Keisaku Fujimoto, Department of Clinical Laboratory Sciences, Shinshu University School of Health Sciences, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan, Tel +81 263 372 393, Fax +81 263 372 370, Email <email>keisaku@shinshu-u.ac.jp</email></corresp></author-notes><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>29</day><month>7</month><year>2014</year></pub-date><volume>9</volume><fpage>805</fpage><lpage>811</lpage><permissions><copyright-statement>&#x000a9; 2014 Kitaguchi et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution &#x02013; Non Commercial (unported, v3.0) License</copyright-statement><copyright-year>2014</copyright-year><license><license-p>The full terms of the License are available at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.</license-p></license></permissions><abstract><sec><title>Background</title><p>The syndrome of combined pulmonary fibrosis and emphysema (CPFE) is a recently described entity associating upper-lobe emphysema and lower-lobe fibrosis. We sought to evaluate differences in pulmonary function between CPFE patients with and without airflow obstruction.</p></sec><sec><title>Subjects and methods</title><p>Thirty-one CPFE patients were divided into two groups according to the presence or absence of irreversible airflow obstruction based on spirometry (forced expiratory volume in 1 second/forced vital capacity &#x0003c;70% following inhalation of a &#x003b2;<sub>2</sub>-agonist) as follows: CPFE patients with airflow obstruction (CPFE OB<sup>+</sup> group, n=11), and CPFE patients without airflow obstruction (CPFE OB<sup>&#x02212;</sup> group, n=20). Pulmonary function, including respiratory impedance evaluated using impulse oscillometry and dynamic hyperinflation following metronome-paced incremental hyperventilation, was retrospectively analyzed in comparison with that observed in 49 chronic obstructive pulmonary disease (COPD) patients (n=49).</p></sec><sec><title>Results</title><p>In imaging findings, low-attenuation-area scores on chest high-resolution computed tomography, representing the degree of emphysema, were significantly lower in the CPFE OB<sup>&#x02212;</sup> group than in the CPFE OB<sup>+</sup> and COPD groups. In contrast, the severity of pulmonary fibrosis was greater in the CPFE OB<sup>&#x02212;</sup> group than in the CPFE OB<sup>+</sup> group. In pulmonary function, lung hyperinflation was not apparent in the CPFE OB<sup>&#x02212;</sup> group. Impairment of diffusion capacity was severe in both the CPFE OB<sup>&#x02212;</sup> and CPFE OB<sup>+</sup> groups. Impulse oscillometry showed that respiratory resistance was not apparent in the CPFE OB<sup>&#x02212;</sup> group compared with the COPD group, and that easy collapsibility of small airways during expiration of tidal breath was not apparent in the CPFE OB<sup>+</sup> group compared with the COPD group. Dynamic hyperinflation following metronome-paced incremental hyperventilation was significantly greater in the COPD group than in the CPFE OB<sup>&#x02212;</sup> group, and also tended to be greater in the CPFE OB<sup>+</sup> group than in the CPFE OB<sup>&#x02212;</sup> group.</p></sec><sec><title>Conclusion</title><p>The mechanisms underlying impairment of physiological function may differ among CPFE OB<sup>+</sup> patients, CPFE OB<sup>&#x02212;</sup> patients, and COPD patients. CPFE is a heterogeneous disease, and may have distinct phenotypes physiologically and radiologically.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>CPFE</kwd><kwd>COPD</kwd><kwd>respiratory impedance</kwd><kwd>dynamic hyperinflation</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>The syndrome of combined pulmonary fibrosis and emphysema (CPFE) is a recently described entity associating upper-lobe emphysema and lower-lobe fibrosis.<xref rid="b1-copd-9-805" ref-type="bibr">1</xref>&#x02013;<xref rid="b5-copd-9-805" ref-type="bibr">5</xref> In pulmonary function, CPFE is characterized by relatively normal spirometric values with mild airflow obstruction and mild lung hyperinflation, severe impairment of gas exchange, and desaturation during exercise.<xref rid="b1-copd-9-805" ref-type="bibr">1</xref>&#x02013;<xref rid="b5-copd-9-805" ref-type="bibr">5</xref> The relatively normal spirometric values observed in patients with CPFE are usually attributed to the counterbalancing effects of the restrictive defect of pulmonary fibrosis and propensity for hyperinflation seen in emphysema. Moreover, preserved airflow may also be explained by increased traction caused by pulmonary fibrosis, preventing the typical expiratory airway collapse seen in emphysema and contributing to stiffening/support of the small airways by peribronchial fibrosis, resulting in the preservation of forced expiratory volume in 1 second (FEV<sub>1</sub>).<xref rid="b6-copd-9-805" ref-type="bibr">6</xref> However, some patients with CPFE who show airflow obstruction defined as FEV<sub>1</sub>/forced vital capacity (FVC) &#x0003c;70% following inhalation of &#x003b2;<sub>2</sub>-agonists are sometimes seen in clinical practice. It is unclear whether CPFE patients with airflow obstruction (CPFE OB<sup>+</sup>) have different clinical characteristics from CPFE patients without airflow obstruction (CPFE OB<sup>&#x02212;</sup>) or not.</p><p>The pathology and imaging findings observed in patients with CPFE are heterogeneous.<xref rid="b2-copd-9-805" ref-type="bibr">2</xref> The relative contributions of the pathological changes of emphysema and fibrosis can vary among patients with CPFE. In imaging findings, CPFE occurs as the development of fibrosis superimposed on a known history of emphysema that may modify the disease progression in most cases.<xref rid="b7-copd-9-805" ref-type="bibr">7</xref> However, it is unclear whether emphysematous and fibrotic lesions progress independently or if one is the result of the development of the other. Therefore, physiological, pathological, and radiological heterogeneity may be characteristic of CPFE.</p><p>We hypothesized that mechanisms underlying lung-function impairment may differ between CPFE patients with and without airflow obstruction. In order to clarify this hypothesis, pulmonary function, including respiratory impedance evaluated using impulse oscillometry (IOS) and dynamic hyperinflation following metronome-paced incremental hyperventilation (MPIH), was retrospectively analyzed in CPFE OB<sup>+</sup> and CPFE OB<sup>&#x02212;</sup> patients in comparison with that observed in chronic obstructive pulmonary disease (COPD) patients.</p></sec><sec sec-type="methods"><title>Subjects and methods</title><sec sec-type="subjects"><title>Subjects</title><p>This study details the retrospective analysis of 31 stable CPFE patients with concurrent emphysema and idiopathic diffuse parenchymal lung disease with fibrosis on chest high-resolution computed tomography (HRCT)<xref rid="b8-copd-9-805" ref-type="bibr">8</xref>,<xref rid="b9-copd-9-805" ref-type="bibr">9</xref> who met our imaging criteria. These patients were seen at the outpatient clinic of Shinshu University Hospital between October 2009 and October 2012. The CPFE patients were divided into two groups according to the presence or absence of irreversible airflow obstruction based on spirometry (FEV<sub>1</sub>/FVC &#x0003c;70% following inhalation of &#x003b2;<sub>2</sub>-agonists) as follows: CPFE OB<sup>+</sup> group, n=11; CPFE OB<sup>&#x02212;</sup> group, n=20.</p><p>The CPFE patients were compared with 49 stable COPD patients who met our imaging criteria. These patients were seen at the outpatient clinic of Shinshu University Hospital between October 2009 and October 2012 (COPD group). The diagnosis of COPD was based on the clinical history and symptoms, including dyspnea during exercise and pulmonary function characterized by irreversible airflow obstruction (FEV<sub>1</sub>/FVC &#x0003c;70% following inhalation of a &#x003b2;<sub>2</sub>-agonist), in accordance with GOLD (Global initiative for chronic Obstructive Lung Disease) guidelines.<xref rid="b10-copd-9-805" ref-type="bibr">10</xref></p><p>Stable patients were defined as those who had not suffered from respiratory tract infections or exacerbation of COPD or pulmonary fibrosis during the preceding 3 months. This study was approved by the institutional research ethics committee of Shinshu University School of Medicine.</p></sec><sec><title>Imaging criteria</title><p>Emphysema and diffuse parenchymal lung disease with significant pulmonary fibrosis were evaluated using chest HRCT as previously described.<xref rid="b11-copd-9-805" ref-type="bibr">11</xref>,<xref rid="b12-copd-9-805" ref-type="bibr">12</xref> Briefly, emphysema was scored visually in the bilateral upper, middle, and lower lung fields according to the methods of Goddard et al.<xref rid="b8-copd-9-805" ref-type="bibr">8</xref> The score for each of the six dimensions was calculated according to percentage of low-attenuation area (%LAA) in each lung field, as follows: score 0, %LAA &#x0003c;5%; score 1, 5%&#x02264; %LAA &#x0003c;25%; score 2, 25%&#x02264; %LAA &#x0003c;50%; score 3, 50%&#x02264; %LAA &#x0003c;75%; and score 4, %LAA&#x02265;75%. The severity of emphysema was graded in accordance with the sum of the scores of the six dimensions, as follows: grade 0, total score 0; grade 1, total score 1&#x02013;6; grade 2, total score 7&#x02013;12; grade 3, total score 13&#x02013;18; and grade 4, total score 19&#x02013;24. The detection of diffuse parenchymal lung disease with significant pulmonary fibrosis on HRCT, defined as the presence of thick-walled bulla, honeycombing, reticular opacity, ground-glass opacity, consolidation, traction bronchiectasis, peribronchovascular interstitial thickening, and architectural distortion, was performed as previously described.<xref rid="b3-copd-9-805" ref-type="bibr">3</xref>,<xref rid="b13-copd-9-805" ref-type="bibr">13</xref> The degree of pulmonary fibrosis was scored visually to grade the severity as previously described.<xref rid="b14-copd-9-805" ref-type="bibr">14</xref></p><p>Computed tomography (CT) images were analyzed independently by two pulmonologists (YK and KF) with no knowledge of the patients&#x02019; clinical information. CPFE patients were characterized by the coexistence of significant emphysema (grade 2 or more, %LAA &#x02265;25%) and diffuse parenchymal lung disease with significant pulmonary fibrosis. COPD patients were characterized by the presence of significant emphysema (grade 2 or more, %LAA &#x02265;25%) without significant pulmonary fibrosis.</p></sec><sec><title>Pulmonary function tests</title><p>Spirometry and diffusing capacity of the lung for carbon monoxide (D<sub>LCO</sub>) were measured using the Chestac-8800 (Chest MI, Tokyo, Japan). Thoracic gas volume was measured using Body Box (MGC Diagnostics, Ann Arbor, MI, USA), after which the subject immediately inspired to total lung capacity (TLC) and expired maximally to residual volume (RV), allowing calculation of lung volumes and RV/TLC. Local Japanese reference data,<xref rid="b15-copd-9-805" ref-type="bibr">15</xref> developed by the Japanese Respiratory Society, were used to derive predicted values for FEV<sub>1</sub> and vital capacity, while the predicted values for D<sub>LCO</sub> and lung volumes (thoracic gas volume, RV, and TLC) measured by body plethysmography were determined using the formulas described by Nishida et al<xref rid="b16-copd-9-805" ref-type="bibr">16</xref> and Boren et al,<xref rid="b17-copd-9-805" ref-type="bibr">17</xref> respectively.</p><p>Respiratory impedance was measured using IOS (MasterScreen&#x02122; IOS; CareFusion, H&#x000f6;chberg, Germany), as previously described.<xref rid="b18-copd-9-805" ref-type="bibr">18</xref>,<xref rid="b19-copd-9-805" ref-type="bibr">19</xref> Respiratory resistance (Rrs) and reactance (Xrs) at lower oscillation frequencies and Rrs at higher frequencies were evaluated at oscillation frequencies of 5 Hz (Rrs5 and Xrs5) and 20 Hz (Rrs20). We also measured the mean values of Xrs5 in separated inspiration and expiration of tidal breath, and evaluated the difference between the mean expiratory and inspiratory reactance (&#x00394;Xrs5).</p></sec><sec><title>Evaluation of dynamic hyperinflation following MPIH</title><p>Dynamic hyperinflation was evaluated using MPIH by incrementally increasing the respiratory rate to 20, 30, and 40 breaths/minute as per our previous reports.<xref rid="b20-copd-9-805" ref-type="bibr">20</xref>,<xref rid="b21-copd-9-805" ref-type="bibr">21</xref> Inspiratory capacity (IC) was measured immediately after breathing at a resting respiratory rate for 30 seconds. The respiratory rate was increased to 20, 30, and 40 breaths/minute in 30-second increments, and IC was again measured immediately after MPIH for 30 seconds at each respiratory rate. IC at the resting respiratory rate was expressed as IC<sub>at rest</sub>. IC at rates of 20, 30, and 40 breaths per minute was expressed as IC<sub>20</sub>, IC<sub>30</sub>, and IC<sub>40</sub>, respectively. Dynamic hyperinflation was evaluated according to the decrease in IC from ICat rest to IC<sub>20</sub>, the decrease in IC from IC<sub>at rest</sub> to IC<sub>30</sub>, and the decrease in IC from ICat rest to IC<sub>40</sub>.</p></sec><sec sec-type="methods"><title>Data analysis</title><p>The values shown in the text, figures, and tables represent the means &#x000b1; standard error of the mean. The data distribution of the variables in the various groups was first assessed using Bartlett&#x02019;s test. When the data for the variables showed a normal distribution, they were compared using one-way analysis of variance, followed by multiple comparisons according to the Tukey&#x02013;Kramer method. When the data for the variables did not show a normal distribution, the variables were compared using the Kruskal&#x02013;Wallis test, followed by multiple comparisons among groups with the nonparametric Tukey&#x02013;Kramer method. Simple correlations between variables were examined by calculating Pearson&#x02019;s product correlation coefficient. Categorical variables of the severity of pulmonary fibrosis on chest HRCT were evaluated using Fisher&#x02019;s exact test. All statistical analyses were performed using Windows-compatible software (StatFlex version 5.0; Artech Co., Ltd., Osaka, Japan). <italic>P</italic>-values less than 0.05 were considered to be significant in all statistical analyses.</p></sec></sec><sec sec-type="results"><title>Results</title><p>Clinical characteristics and pulmonary function parameters of the CPFE OB<sup>&#x02212;</sup>, CPFE OB<sup>+</sup>, and COPD groups are shown in <xref ref-type="table" rid="t1-copd-9-805">Table 1</xref>. In imaging findings, LAA scores on chest HRCT were significantly lower in the CPFE OB<sup>&#x02212;</sup> group than in the CPFE OB<sup>+</sup> and COPD groups. Significantly more patients showed minimum pulmonary fibrosis in the CPFE OB<sup>+</sup> group than in the CPFE OB<sup>&#x02212;</sup> group, which suggests that the severity of pulmonary fibrosis was greater in the CPFE OB<sup>&#x02212;</sup> group. In pulmonary function, percentage-predicted D<sub>LCO</sub> was significantly lower in the CPFE OB<sup>&#x02212;</sup> and CPFE OB<sup>+</sup> groups than in the COPD group. DLco corrected for alveolar volume (VA), (D<sub>LCO</sub>/VA). Percentage-predicted D<sub>LCO</sub>/VA was significantly lower in the CPFE OB<sup>+</sup> group than in the CPFE OB<sup>&#x02212;</sup> and COPD groups. There was a significant correlation between LAA scores and D<sub>LCO</sub>/VA among all CPFE patients (<italic>r</italic>=&#x02212;0.76, <italic>P</italic>=0.0003).</p><p>Rrs5, Rrs20, and Rrs5&#x02013;Rrs20 were significantly lower in the CPFE OB<sup>&#x02212;</sup> group than in the COPD group (<xref ref-type="fig" rid="f1-copd-9-805">Figure 1</xref>). These parameters tended to be higher in the CPFE OB<sup>+</sup> group than in the CPFE OB<sup>&#x02212;</sup> group, although there were no significant differences. Xrs5 was significantly less negative in the CPFE OB<sup>&#x02212;</sup> group than in the COPD group. &#x00394;Xrs5, indicating the difference in mean Xrs5 during the inspiration and expiration phases and representing easy collapsibility of small airways during expiration of the tidal breath, was significantly greater in the COPD group than in the CPFE OB<sup>+</sup> group.</p><sec><title>Dynamic hyperinflation following MPIH</title><p>IC at rest was significantly lower in the CPFE OB<sup>&#x02212;</sup> group than in the CPFE OB<sup>+</sup> and COPD groups (<xref ref-type="fig" rid="f2-copd-9-805">Figure 2</xref>). Although there were no significant differences in IC<sub>20</sub>, IC<sub>30</sub>, and IC<sub>40</sub> among the three groups, these parameters tended to be lower in the CPFE OB<sup>&#x02212;</sup> group. IC incrementally decreased as the respiratory rate was incrementally increased in the COPD group only. IC<sub>rest-20</sub>, IC<sub>rest-30</sub> and IC<sub>rest-40</sub>, representing dynamic hyperinflation, had significantly more negative values in the COPD group than in the CPFE OB<sup>&#x02212;</sup> group (<xref ref-type="fig" rid="f3-copd-9-805">Figure 3</xref>). These variables tended to be more negative in the CPFE OB<sup>+</sup> group than in the CPFE OB<sup>&#x02212;</sup> group, although there were no significant differences.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>This is the first report to evaluate pulmonary function impairment in CPFE patients divided into two groups according to the presence or absence of airflow obstruction based on spirometry. LAA scores, representing the degree of emphysema on chest HRCT, were significantly higher in the CPFE OB<sup>+</sup> group than in the CPFE OB<sup>&#x02212;</sup> group. In contrast, more patients showed minimum pulmonary fibrosis in the CPFE OB<sup>+</sup> group than in the CPFE OB<sup>&#x02212;</sup> group. Impairment of diffusion capacity was severe in both the CPFE OB<sup>&#x02212;</sup> and CPFE OB<sup>+</sup> groups. Neither lung hyperinflation nor respiratory resistance were apparent in the CPFE OB<sup>&#x02212;</sup> group. Easy collapsibility of small airways during expiration of the tidal breath, expressed as &#x00394;Xrs5, was not apparent in the CPFE OB<sup>+</sup> group compared with the COPD group. Dynamic hyperinflation following MPIH expressed as IC<sub>rest-20</sub>, IC<sub>rest-30</sub>, and IC<sub>rest-40</sub> was significantly greater in the COPD group than in the CPFE OB<sup>&#x02212;</sup> group and also tended to be greater in the CPFE OB<sup>+</sup> group than in the CPFE OB<sup>&#x02212;</sup> group.</p><p>We found that the proportions of emphysema and pulmonary fibrosis on chest HRCT were different between the CPFE OB<sup>+</sup> and CPFE OB<sup>&#x02212;</sup> groups in the present study. There is a possibility that CPFE is associated with clinical phenotypes that can be classified according to the findings on chest HRCT. That is to say, CPFE may be classified into the &#x0201c;emphysema-dominant&#x0201d; phenotype or the &#x0201c;fibrosis-dominant&#x0201d; phenotype, which may involve different mechanisms underlying pulmonary function impairment, such as irreversible airflow obstruction and dynamic hyperinflation. These findings may thus allow us to significantly improve our understanding of radiological and physiological heterogeneity of CPFE.</p><p>Our previous study revealed that the annual decrease in D<sub>LCO</sub> and D<sub>LCO</sub>/VA was greater in CPFE patients than in COPD patients.<xref rid="b13-copd-9-805" ref-type="bibr">13</xref> Longitudinal changes in D<sub>LCO</sub> have been shown to have prognostic value in patients with idiopathic pulmonary fibrosis.<xref rid="b22-copd-9-805" ref-type="bibr">22</xref>&#x02013;<xref rid="b25-copd-9-805" ref-type="bibr">25</xref> These findings suggest that it is helpful to measure longitudinal changes in D<sub>LCO</sub>/VA as a prognostic predictor in CPFE patients. Indeed, severe D<sub>LCO</sub>/VA reduction is frequently related to pulmonary hypertension,<xref rid="b26-copd-9-805" ref-type="bibr">26</xref> which is often observed in CPFE patients.<xref rid="b1-copd-9-805" ref-type="bibr">1</xref>,<xref rid="b27-copd-9-805" ref-type="bibr">27</xref> The presence of pulmonary hypertension is a critical determinant of the prognosis of CPFE.<xref rid="b1-copd-9-805" ref-type="bibr">1</xref>,<xref rid="b28-copd-9-805" ref-type="bibr">28</xref> In the present study, D<sub>LCO</sub>/VA was significantly lower in the CPFE OB<sup>+</sup> group. We also found a significant correlation between D<sub>LCO</sub>/VA and the degree of emphysema on chest HRCT among all CPFE patients. These findings suggest that CPFE OB<sup>+</sup> patients with more emphysema have worse survival than CPFE OB<sup>&#x02212;</sup> patients. Further studies are needed to investigate the association between survival and airflow obstruction in CPFE patients.</p><p>The parameters of respiratory impedance measured using IOS were relatively normal in the CPFE OB<sup>&#x02212;</sup> group, despite the presence of emphysema, compared with those observed in the healthy control group in our previous study.<xref rid="b19-copd-9-805" ref-type="bibr">19</xref> Interestingly, in the present study, &#x00394;Xrs5 was significantly lower in the CPFE OB<sup>+</sup> group than in the COPD group, despite the presence of more emphysema, whereas Rrs5, Rrs20, and Rrs5&#x02013;Rrs20 tended to be higher in the CPFE OB<sup>+</sup> group than in the CPFE OB<sup>&#x02212;</sup> group. When airflow obstruction is present, the oscillatory signal cannot pass through the choke points to reach the alveoli,<xref rid="b29-copd-9-805" ref-type="bibr">29</xref> resulting in a marked reduction in apparent compliance; therefore, the value of Xrs5 changes to be more negative physiologically in COPD patients.<xref rid="b30-copd-9-805" ref-type="bibr">30</xref> &#x00394;Xrs5 has been suggested to reflect the number and distribution of choke points within the bronchial tree, representing the overall distribution of expiratory flow limitation during tidal breathing in COPD patients.<xref rid="b31-copd-9-805" ref-type="bibr">31</xref>&#x02013;<xref rid="b33-copd-9-805" ref-type="bibr">33</xref> These findings suggest that increased traction caused by pulmonary fibrosis prevents airway collapsibility during expiration of the tidal breath as a result of loss of alveolar attachment and elastic recoil at the site of small airways in CPFE patients. &#x00394;Xrs5 may be a useful indicator for making a diagnosis of CPFE and evaluating the extent of fibrotic component in CPFE physiologically.</p><p>The parameters of dynamic hyperinflation following MPIH were relatively normal in the CPFE OB<sup>&#x02212;</sup> group, despite the presence of emphysema, compared with those observed in the healthy control group in our previous study,<xref rid="b20-copd-9-805" ref-type="bibr">20</xref> suggesting that dynamic hyperinflation is not associated with pulmonary function impairment in CPFE OB patients without airflow obstruction. However, there is a possibility that dynamic hyperinflation is associated with pulmonary function impairment in some CPFE OB<sup>+</sup> patients as well as in COPD patients. Further studies involving a larger number of patients are needed to confirm the present results. On the other hand, a previous study revealed that pulmonary hypertension is often observed in CPFE patients,<xref rid="b1-copd-9-805" ref-type="bibr">1</xref>,<xref rid="b27-copd-9-805" ref-type="bibr">27</xref>&#x02013;<xref rid="b28-copd-9-805" ref-type="bibr">28</xref> and is associated with dyspnea during exercise and/or decreased exercise tolerance in CPFE patients.<xref rid="b28-copd-9-805" ref-type="bibr">28</xref> Pulmonary hypertension may thus influence pulmonary function impairment in CPFE patients. Indeed, severe D<sub>LCO</sub>/VA reduction is frequently related to pulmonary hypertension.<xref rid="b26-copd-9-805" ref-type="bibr">26</xref></p><p>There were several limitations in this study. First, this was a single-center, uncontrolled-design retrospective study with a lack of statistical power, as the sample size was small in the CPFE OB<sup>+</sup> group (n=11). This study was performed to reveal that CPFE is a heterogeneous disease and has distinct phenotypes physiologically, in spite of the small sample size. Additional prospective studies with large sample sizes are required to confirm our results. Second, the assessment of emphysema on chest HRCT was performed according to a visual scoring method, rather than software-based quantification of the degree of emphysema. However, the reproducibility of visual scoring was demonstrated in our previous report.<xref rid="b12-copd-9-805" ref-type="bibr">12</xref> In addition, we did not measure the exact areas of fibrosis on chest HRCT. CPFE was diagnosed according to our criteria as previously described.<xref rid="b3-copd-9-805" ref-type="bibr">3</xref>,<xref rid="b13-copd-9-805" ref-type="bibr">13</xref> Third, the differences in pharmacotherapy between the CPFE and COPD groups might have influenced the results.</p><p>In conclusion, the mechanisms underlying impairment of physiological function may differ among CPFE OB<sup>+</sup> patients, CPFE OB<sup>&#x02212;</sup> patients, and COPD patients. CPFE is a heterogeneous disease, and may have distinct phenotypes physiologically and radiologically.</p></sec></body><back><fn-group><fn><p><bold>Disclosure</bold></p><p>The authors report no conflicts of interest in this work.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-copd-9-805"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cottin</surname><given-names>V</given-names></name><name><surname>Nunes</surname><given-names>H</given-names></name><name><surname>Brillet</surname><given-names>PY</given-names></name><etal/></person-group><article-title>Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity</article-title><source>Eur Respir J</source><year>2005</year><volume>26</volume><fpage>586</fpage><lpage>593</lpage><pub-id pub-id-type="pmid">16204587</pub-id></element-citation></ref><ref id="b2-copd-9-805"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jankowich</surname><given-names>MD</given-names></name><name><surname>Polsky</surname><given-names>M</given-names></name><name><surname>Klein</surname><given-names>M</given-names></name><name><surname>Rounds</surname><given-names>S</given-names></name></person-group><article-title>Heterogeneity in combined pulmonary fibrosis and emphysema</article-title><source>Respiration</source><year>2008</year><volume>75</volume><fpage>411</fpage><lpage>417</lpage><pub-id pub-id-type="pmid">17684315</pub-id></element-citation></ref><ref id="b3-copd-9-805"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kitaguchi</surname><given-names>Y</given-names></name><name><surname>Fujimoto</surname><given-names>K</given-names></name><name><surname>Hanaoka</surname><given-names>M</given-names></name><name><surname>Kawakami</surname><given-names>S</given-names></name><name><surname>Honda</surname><given-names>T</given-names></name><name><surname>Kubo</surname><given-names>K</given-names></name></person-group><article-title>Clinical characteristics of combined pulmonary fibrosis and emphysema</article-title><source>Respirology</source><year>2010</year><volume>15</volume><fpage>265</fpage><lpage>271</lpage><pub-id pub-id-type="pmid">20051048</pub-id></element-citation></ref><ref id="b4-copd-9-805"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grubstein</surname><given-names>A</given-names></name><name><surname>Bendayan</surname><given-names>D</given-names></name><name><surname>Schactman</surname><given-names>I</given-names></name><name><surname>Cohen</surname><given-names>M</given-names></name><name><surname>Shitrit</surname><given-names>D</given-names></name><name><surname>Kramer</surname><given-names>MR</given-names></name></person-group><article-title>Concomitant upper-lobe bullous emphysema, lower-lobe interstitial fibrosis and pulmonary hypertension in heavy smokers: report of eight cases and review of the literature</article-title><source>Respir Med</source><year>2005</year><volume>99</volume><fpage>948</fpage><lpage>954</lpage><pub-id pub-id-type="pmid">15950135</pub-id></element-citation></ref><ref id="b5-copd-9-805"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mura</surname><given-names>M</given-names></name><name><surname>Zompatori</surname><given-names>M</given-names></name><name><surname>Pacilli</surname><given-names>AM</given-names></name><name><surname>Fasano</surname><given-names>L</given-names></name><name><surname>Schiavina</surname><given-names>M</given-names></name><name><surname>Fabbri</surname><given-names>M</given-names></name></person-group><article-title>The presence of emphysema further impairs physiologic function in patients with idiopathic pulmonary fibrosis</article-title><source>Respir Care</source><year>2006</year><volume>51</volume><fpage>257</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">16533415</pub-id></element-citation></ref><ref id="b6-copd-9-805"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jankowich</surname><given-names>MD</given-names></name><name><surname>Rounds</surname><given-names>SI</given-names></name></person-group><article-title>Combined pulmonary fibrosis and emphysema syndrome: a review</article-title><source>Chest</source><year>2012</year><volume>141</volume><fpage>222</fpage><lpage>231</lpage><pub-id pub-id-type="pmid">22215830</pub-id></element-citation></ref><ref id="b7-copd-9-805"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cottin</surname><given-names>V</given-names></name></person-group><article-title>The impact of emphysema in pulmonary fibrosis</article-title><source>Eur Respir Rev</source><year>2013</year><volume>22</volume><fpage>153</fpage><lpage>157</lpage><pub-id pub-id-type="pmid">23728869</pub-id></element-citation></ref><ref id="b8-copd-9-805"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goddard</surname><given-names>PR</given-names></name><name><surname>Nicholson</surname><given-names>EM</given-names></name><name><surname>Laszlo</surname><given-names>G</given-names></name><name><surname>Watt</surname><given-names>I</given-names></name></person-group><article-title>Computed tomography in pulmonary emphysema</article-title><source>Clin Radiol</source><year>1982</year><volume>33</volume><fpage>379</fpage><lpage>387</lpage><pub-id pub-id-type="pmid">7083738</pub-id></element-citation></ref><ref id="b9-copd-9-805"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gotway</surname><given-names>MB</given-names></name><name><surname>Freemer</surname><given-names>MM</given-names></name><name><surname>King</surname><given-names>TE</given-names><suffix>Jr</suffix></name></person-group><article-title>Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias</article-title><source>Thorax</source><year>2007</year><volume>62</volume><fpage>546</fpage><lpage>553</lpage><pub-id pub-id-type="pmid">17536033</pub-id></element-citation></ref><ref id="b10-copd-9-805"><label>10</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Global initiative for chronic Obstructive Lung Disease</collab></person-group><source>Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease</source><publisher-loc>Bethesda (MD)</publisher-loc><publisher-name>GOLD</publisher-name><year>2013</year></element-citation></ref><ref id="b11-copd-9-805"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kitaguchi</surname><given-names>Y</given-names></name><name><surname>Fujimoto</surname><given-names>K</given-names></name><name><surname>Kubo</surname><given-names>K</given-names></name><name><surname>Honda</surname><given-names>T</given-names></name></person-group><article-title>Characteristics of COPD phenotypes classified according to the findings of HRCT</article-title><source>Respir Med</source><year>2006</year><volume>100</volume><fpage>1742</fpage><lpage>1752</lpage><pub-id pub-id-type="pmid">16549342</pub-id></element-citation></ref><ref id="b12-copd-9-805"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujimoto</surname><given-names>K</given-names></name><name><surname>Kitaguchi</surname><given-names>Y</given-names></name><name><surname>Kubo</surname><given-names>K</given-names></name><name><surname>Honda</surname><given-names>T</given-names></name></person-group><article-title>Clinical analysis of chronic obstructive pulmonary disease phenotypes classified using high-resolution computed tomography</article-title><source>Respirology</source><year>2006</year><volume>11</volume><fpage>731</fpage><lpage>740</lpage><pub-id pub-id-type="pmid">17052301</pub-id></element-citation></ref><ref id="b13-copd-9-805"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kitaguchi</surname><given-names>Y</given-names></name><name><surname>Fujimoto</surname><given-names>K</given-names></name><name><surname>Hayashi</surname><given-names>R</given-names></name><name><surname>Hanaoka</surname><given-names>M</given-names></name><name><surname>Honda</surname><given-names>T</given-names></name><name><surname>Kubo</surname><given-names>K</given-names></name></person-group><article-title>Annual changes in pulmonary function in combined pulmonary fibrosis and emphysema: over a 5-year follow-up</article-title><source>Respir Med</source><year>2013</year><volume>107</volume><fpage>1986</fpage><lpage>1992</lpage><pub-id pub-id-type="pmid">23850272</pub-id></element-citation></ref><ref id="b14-copd-9-805"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurashima</surname><given-names>K</given-names></name><name><surname>Takayanagi</surname><given-names>N</given-names></name><name><surname>Tsuchiya</surname><given-names>N</given-names></name><etal/></person-group><article-title>The effect of emphysema on lung function and survival in patients with idiopathic pulmonary fibrosis</article-title><source>Respirology</source><year>2010</year><volume>15</volume><fpage>843</fpage><lpage>848</lpage><pub-id pub-id-type="pmid">20546187</pub-id></element-citation></ref><ref id="b15-copd-9-805"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Japanese Society of Chest Disease</collab></person-group><article-title>Standards of pulmonary function tests for Japanese</article-title><source>Jpn J Respir Dis</source><year>1993</year><volume>31</volume><fpage>421</fpage><lpage>427</lpage></element-citation></ref><ref id="b16-copd-9-805"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishida</surname><given-names>S</given-names></name><name><surname>Kambe</surname><given-names>M</given-names></name><name><surname>Sewake</surname><given-names>N</given-names></name><name><surname>Takano</surname><given-names>M</given-names></name><name><surname>Kawane</surname><given-names>H</given-names></name></person-group><article-title>Pulmonary function in healthy subjects and its prediction. 5. Pulmonary diffusing capacity in adults</article-title><source>Rinsho Byori</source><year>1976</year><volume>24</volume><fpage>941</fpage><lpage>947</lpage><comment>Japanese</comment><pub-id pub-id-type="pmid">1034788</pub-id></element-citation></ref><ref id="b17-copd-9-805"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boren</surname><given-names>HG</given-names></name><name><surname>Kory</surname><given-names>RC</given-names></name><name><surname>Syner</surname><given-names>JC</given-names></name><name><surname>Callahan</surname><given-names>R</given-names></name></person-group><article-title>The Veterans Administration-Army cooperative study of pulmonary function. 2. The lung volume and its subdivisions in normal men</article-title><source>Am J Med</source><year>1966</year><volume>41</volume><fpage>96</fpage><lpage>101</lpage></element-citation></ref><ref id="b18-copd-9-805"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van de Woestijne</surname><given-names>KP</given-names></name><name><surname>Desager</surname><given-names>KN</given-names></name><name><surname>Duiverman</surname><given-names>EJ</given-names></name><name><surname>Marchal</surname><given-names>F</given-names></name></person-group><article-title>Recommendations for measurement of respiratory input impedance by means of the forced oscillation method</article-title><source>Eur Respir Rev</source><year>1994</year><volume>19</volume><fpage>235</fpage><lpage>237</lpage></element-citation></ref><ref id="b19-copd-9-805"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanda</surname><given-names>S</given-names></name><name><surname>Fujimoto</surname><given-names>K</given-names></name><name><surname>Komatsu</surname><given-names>Y</given-names></name><name><surname>Yasuo</surname><given-names>M</given-names></name><name><surname>Hanaoka</surname><given-names>M</given-names></name><name><surname>Kubo</surname><given-names>K</given-names></name></person-group><article-title>Evaluation of respiratory impedance in asthma and COPD by an impulse oscillation system</article-title><source>Intern Med</source><year>2010</year><volume>49</volume><fpage>23</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">20045997</pub-id></element-citation></ref><ref id="b20-copd-9-805"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujimoto</surname><given-names>K</given-names></name><name><surname>Yoshiike</surname><given-names>F</given-names></name><name><surname>Yasuo</surname><given-names>M</given-names></name><etal/></person-group><article-title>Effects of bronchodilators on dynamic hyperinflation following hyperventilation in patients with COPD</article-title><source>Respirology</source><year>2007</year><volume>12</volume><fpage>93</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">17207032</pub-id></element-citation></ref><ref id="b21-copd-9-805"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujimoto</surname><given-names>K</given-names></name><name><surname>Kitaguchi</surname><given-names>Y</given-names></name><name><surname>Kanda</surname><given-names>S</given-names></name><name><surname>Urushihata</surname><given-names>K</given-names></name><name><surname>Hanaoka</surname><given-names>M</given-names></name><name><surname>Kubo</surname><given-names>K</given-names></name></person-group><article-title>Comparison of efficacy of long-acting bronchodilators in emphysema dominant and emphysema nondominant chronic obstructive pulmonary disease</article-title><source>Int J Chron Obstruct Pulmon Dis</source><year>2011</year><volume>6</volume><fpage>219</fpage><lpage>227</lpage><pub-id pub-id-type="pmid">21660299</pub-id></element-citation></ref><ref id="b22-copd-9-805"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>DA</given-names></name><name><surname>Helmers</surname><given-names>RA</given-names></name><name><surname>Galvin</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Determinants of survival in idiopathic pulmonary fibrosis</article-title><source>Am J Respir Crit Care Med</source><year>1994</year><volume>149</volume><fpage>450</fpage><lpage>454</lpage><pub-id pub-id-type="pmid">8306044</pub-id></element-citation></ref><ref id="b23-copd-9-805"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flaherty</surname><given-names>KR</given-names></name><name><surname>Mumford</surname><given-names>JA</given-names></name><name><surname>Murray</surname><given-names>S</given-names></name><etal/></person-group><article-title>Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia</article-title><source>Am J Respir Crit Care Med</source><year>2003</year><volume>168</volume><fpage>543</fpage><lpage>548</lpage><pub-id pub-id-type="pmid">12773329</pub-id></element-citation></ref><ref id="b24-copd-9-805"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collard</surname><given-names>HR</given-names></name><name><surname>King</surname><given-names>TE</given-names><suffix>Jr</suffix></name><name><surname>Bartelson</surname><given-names>BB</given-names></name><name><surname>Vourlekis</surname><given-names>JS</given-names></name><name><surname>Schwarz</surname><given-names>MI</given-names></name><name><surname>Brown</surname><given-names>KK</given-names></name></person-group><article-title>Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis</article-title><source>Am J Respir Crit Care Med</source><year>2003</year><volume>168</volume><fpage>538</fpage><lpage>542</lpage><pub-id pub-id-type="pmid">12773325</pub-id></element-citation></ref><ref id="b25-copd-9-805"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flaherty</surname><given-names>KR</given-names></name><name><surname>Andrei</surname><given-names>AC</given-names></name><name><surname>Murray</surname><given-names>S</given-names></name><etal/></person-group><article-title>Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test</article-title><source>Am J Respir Crit Care Med</source><year>2006</year><volume>174</volume><fpage>803</fpage><lpage>809</lpage><pub-id pub-id-type="pmid">16825656</pub-id></element-citation></ref><ref id="b26-copd-9-805"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiakouama</surname><given-names>L</given-names></name><name><surname>Cottin</surname><given-names>V</given-names></name><name><surname>Glerant</surname><given-names>JC</given-names></name><name><surname>Bayle</surname><given-names>JY</given-names></name><name><surname>Mornex</surname><given-names>JF</given-names></name><name><surname>Cordier</surname><given-names>JF</given-names></name></person-group><article-title>Conditions associated with severe carbon monoxide diffusion coefficient reduction</article-title><source>Respir Med</source><year>2011</year><volume>105</volume><fpage>1248</fpage><lpage>1256</lpage><pub-id pub-id-type="pmid">21454061</pub-id></element-citation></ref><ref id="b27-copd-9-805"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mej&#x000ed;a</surname><given-names>M</given-names></name><name><surname>Carrillo</surname><given-names>G</given-names></name><name><surname>Rojas-Serrano</surname><given-names>J</given-names></name><etal/></person-group><article-title>Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension</article-title><source>Chest</source><year>2009</year><volume>136</volume><fpage>10</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">19225068</pub-id></element-citation></ref><ref id="b28-copd-9-805"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cottin</surname><given-names>V</given-names></name><name><surname>Le Pavec</surname><given-names>J</given-names></name><name><surname>Pr&#x000e9;vot</surname><given-names>G</given-names></name><etal/></person-group><article-title>Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome</article-title><source>Eur Respir J</source><year>2010</year><volume>35</volume><fpage>105</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">19643948</pub-id></element-citation></ref><ref id="b29-copd-9-805"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawson</surname><given-names>SV</given-names></name><name><surname>Elliott</surname><given-names>EA</given-names></name></person-group><article-title>Wave-speed limitation on expiratory flow &#x02013; a unifying concept</article-title><source>J Appl Physiol Respir Environ Exerc Physiol</source><year>1977</year><volume>43</volume><fpage>498</fpage><lpage>515</lpage><pub-id pub-id-type="pmid">914721</pub-id></element-citation></ref><ref id="b30-copd-9-805"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Donnell</surname><given-names>DE</given-names></name><name><surname>Voduc</surname><given-names>N</given-names></name><name><surname>Fitzpatrick</surname><given-names>M</given-names></name><name><surname>Webb</surname><given-names>KA</given-names></name></person-group><article-title>Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease</article-title><source>Eur Respir J</source><year>2004</year><volume>24</volume><fpage>86</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">15293609</pub-id></element-citation></ref><ref id="b31-copd-9-805"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dellac&#x000e0;</surname><given-names>RL</given-names></name><name><surname>Santus</surname><given-names>P</given-names></name><name><surname>Aliverti</surname><given-names>A</given-names></name><etal/></person-group><article-title>Detection of expiratory flow limitation in COPD using the forced oscillation technique</article-title><source>Eur Respir J</source><year>2004</year><volume>23</volume><fpage>232</fpage><lpage>240</lpage><pub-id pub-id-type="pmid">14979497</pub-id></element-citation></ref><ref id="b32-copd-9-805"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dellac&#x000e0;</surname><given-names>RL1</given-names></name><name><surname>Rotger</surname><given-names>M</given-names></name><name><surname>Aliverti</surname><given-names>A</given-names></name><name><surname>Navajas</surname><given-names>D</given-names></name><name><surname>Pedotti</surname><given-names>A</given-names></name><name><surname>Farr&#x000e9;</surname><given-names>R</given-names></name></person-group><article-title>Noninvasive detection of expiratory flow limitation in COPD patients during nasal CPAP</article-title><source>Eur Respir J</source><year>2006</year><volume>27</volume><fpage>983</fpage><lpage>991</lpage><pub-id pub-id-type="pmid">16446315</pub-id></element-citation></ref><ref id="b33-copd-9-805"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dellac&#x000e0;</surname><given-names>RL</given-names></name><name><surname>Duffy</surname><given-names>N</given-names></name><name><surname>Pompilio</surname><given-names>PP</given-names></name><etal/></person-group><article-title>Expiratory flow limitation detected by forced oscillation and negative expiratory pressure</article-title><source>Eur Respir J</source><year>2007</year><volume>29</volume><fpage>363</fpage><lpage>374</lpage><pub-id pub-id-type="pmid">17079262</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-copd-9-805" position="float"><label>Figure 1</label><caption><p>Respiratory impedance in the CPFE OB<sup>&#x02212;</sup>, CPFE OB<sup>+</sup>, and COPD groups.</p><p><bold>Notes:</bold> *<italic>P</italic>&#x0003c;0.05, **<italic>P</italic>&#x0003c;0.01 versus COPD. Values are means &#x000b1; standard error of the mean.</p><p><bold>Abbreviations:</bold> CPFE, combined pulmonary fibrosis and emphysema; OB-, without airflow obstruction; OB<sup>+</sup>, with airflow obstruction; COPD, chronic obstructive pulmonary disease; Rrs5, respiratory resistance at 5 Hz; Rrs20, respiratory resistance at 20 Hz; Xrs5, respiratory reactance at 5 Hz; &#x025b3;Xrs5, within-breath changes in Xrs5.</p></caption><graphic xlink:href="copd-9-805Fig1"/></fig><fig id="f2-copd-9-805" position="float"><label>Figure 2</label><caption><p>Inspiratory capacity as the respiratory rate was incrementally increased in the CPFE OB<sup>&#x02212;</sup>, CPFE OB<sup>+</sup>, and COPD groups.</p><p><bold>Notes:</bold> Dynamic hyperinflation following metronome-paced incremental hyperventilation in the combined pulmonary fibrosis and emphysema (CPFE) without airflow obstruction (OB<sup>&#x02212;</sup>), with airflow obstruction (CPFE OB<sup>+</sup>), and chronic obstructive pulmonary disease (COPD) groups. Inspiratory capacity (IC) from resting respiratory rate to rates of 20, 30, and 40 breaths per minute. **<italic>P</italic>&#x0003c;0.01 versus COPD; <sup>&#x02020;</sup><italic>P</italic>&#x0003c;0.05 versus CPFE OB<sup>+</sup>. Values are means &#x000b1; standard error of the mean.</p></caption><graphic xlink:href="copd-9-805Fig2"/></fig><fig id="f3-copd-9-805" position="float"><label>Figure 3</label><caption><p>Decrease in inspiratory capacity from resting respiratory rates to the rate of 20, 30, and 40 breaths per minute, representing dynamic hyperinflation, in the CPFE OB<sup>&#x02212;</sup>, CPFE OB<sup>+</sup>, and COPD groups.</p><p><bold>Notes:</bold> Dynamic hyperinflation following metronome-paced incremental hyperventilation in the combined pulmonary fibrosis and emphysema (CPFE) without airflow obstruction (OB<sup>&#x02212;</sup>), with airflow obstruction (CPFE OB<sup>+</sup>), and chronic obstructive pulmonary disease (COPD) groups. Decrease in inspiratory capacity (IC) from resting respiratory rate to rates of 20, 30, and 40 breaths per minute. *<italic>P</italic>&#x0003c;0.05, **<italic>P</italic>&#x0003c;0.01 versus COPD. Values are means &#x000b1; standard error of the mean.</p></caption><graphic xlink:href="copd-9-805Fig3"/></fig><table-wrap id="t1-copd-9-805" position="float"><label>Table 1</label><caption><p>Characteristics of the combined pulmonary fibrosis and emphysema (CPFE) without airflow obstruction (OB<sup>&#x02212;</sup>), with airflow obstruction (CPFE OB<sup>+</sup>), and chronic obstructive pulmonary disease (COPD) groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">CPFE OB<sup>&#x02212;</sup> (n=20)</th><th align="left" valign="top" rowspan="1" colspan="1">CPFE OB<sup>+</sup> (n=11)</th><th align="left" valign="top" rowspan="1" colspan="1">COPD (n=49)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Age, years</td><td align="left" valign="top" rowspan="1" colspan="1">67.8&#x000b1;2.2</td><td align="left" valign="top" rowspan="1" colspan="1">73.6&#x000b1;1.9</td><td align="left" valign="top" rowspan="1" colspan="1">70.9&#x000b1;1.1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex, male/female</td><td align="left" valign="top" rowspan="1" colspan="1">20/0</td><td align="left" valign="top" rowspan="1" colspan="1">11/0</td><td align="left" valign="top" rowspan="1" colspan="1">44/5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup></td><td align="left" valign="top" rowspan="1" colspan="1">23.8&#x000b1;0.5<xref ref-type="table-fn" rid="tfn1-copd-9-805">*</xref></td><td align="left" valign="top" rowspan="1" colspan="1">22.6&#x000b1;0.9</td><td align="left" valign="top" rowspan="1" colspan="1">21.9&#x000b1;0.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LAA score on chest HRCT</td><td align="left" valign="top" rowspan="1" colspan="1">11.0&#x000b1;1.2<xref ref-type="table-fn" rid="tfn2-copd-9-805">**</xref>,<xref ref-type="table-fn" rid="tfn4-copd-9-805">&#x02020;&#x02020;</xref></td><td align="left" valign="top" rowspan="1" colspan="1">19.5&#x000b1;1.4</td><td align="left" valign="top" rowspan="1" colspan="1">16.2&#x000b1;1.0</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Severity of pulmonary fibrosis on chest HRCT</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Minimum</td><td align="left" valign="top" rowspan="1" colspan="1">7 (35%)<xref ref-type="table-fn" rid="tfn3-copd-9-805">&#x02020;</xref></td><td align="left" valign="top" rowspan="1" colspan="1">8 (72.7%)</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Moderate</td><td align="left" valign="top" rowspan="1" colspan="1">8 (40%)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (18.2%)</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Severe</td><td align="left" valign="top" rowspan="1" colspan="1">5 (25%)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (9.1%)</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Pulmonary function</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;VC, % of predicted</td><td align="left" valign="top" rowspan="1" colspan="1">91.6&#x000b1;5.2<xref ref-type="table-fn" rid="tfn3-copd-9-805">&#x02020;</xref></td><td align="left" valign="top" rowspan="1" colspan="1">108.8&#x000b1;3.4</td><td align="left" valign="top" rowspan="1" colspan="1">97.0&#x000b1;2.6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;FEV<sub>1</sub>, L</td><td align="left" valign="top" rowspan="1" colspan="1">2.43&#x000b1;0.12<xref ref-type="table-fn" rid="tfn2-copd-9-805">**</xref>,<xref ref-type="table-fn" rid="tfn4-copd-9-805">&#x02020;&#x02020;</xref></td><td align="left" valign="top" rowspan="1" colspan="1">1.79&#x000b1;0.13</td><td align="left" valign="top" rowspan="1" colspan="1">1.53&#x000b1;0.09</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;FEV<sub>1</sub>, % of predicted</td><td align="left" valign="top" rowspan="1" colspan="1">87.1&#x000b1;4.9<xref ref-type="table-fn" rid="tfn2-copd-9-805">**</xref>,<xref ref-type="table-fn" rid="tfn4-copd-9-805">&#x02020;&#x02020;</xref></td><td align="left" valign="top" rowspan="1" colspan="1">64.9&#x000b1;4.4</td><td align="left" valign="top" rowspan="1" colspan="1">64.3&#x000b1;3.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;FEV<sub>1</sub>/FVC, %</td><td align="left" valign="top" rowspan="1" colspan="1">79.5&#x000b1;1.5<xref ref-type="table-fn" rid="tfn2-copd-9-805">**</xref>,<xref ref-type="table-fn" rid="tfn4-copd-9-805">&#x02020;&#x02020;</xref></td><td align="left" valign="top" rowspan="1" colspan="1">52.7&#x000b1;3.5</td><td align="left" valign="top" rowspan="1" colspan="1">52.5&#x000b1;1.7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;RV, % of predicted</td><td align="left" valign="top" rowspan="1" colspan="1">82.9&#x000b1;7.2<xref ref-type="table-fn" rid="tfn2-copd-9-805">**</xref>,<xref ref-type="table-fn" rid="tfn4-copd-9-805">&#x02020;&#x02020;</xref></td><td align="left" valign="top" rowspan="1" colspan="1">143.9&#x000b1;16.9<xref ref-type="table-fn" rid="tfn2-copd-9-805">**</xref></td><td align="left" valign="top" rowspan="1" colspan="1">198.0&#x000b1;9.6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;TLC, % of predicted</td><td align="left" valign="top" rowspan="1" colspan="1">83.0&#x000b1;5.0<xref ref-type="table-fn" rid="tfn2-copd-9-805">**</xref>,<xref ref-type="table-fn" rid="tfn4-copd-9-805">&#x02020;&#x02020;</xref></td><td align="left" valign="top" rowspan="1" colspan="1">116.8&#x000b1;6.6</td><td align="left" valign="top" rowspan="1" colspan="1">125.3&#x000b1;3.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;RV/TLC, %</td><td align="left" valign="top" rowspan="1" colspan="1">32.0&#x000b1;2.2<xref ref-type="table-fn" rid="tfn2-copd-9-805">**</xref>,<xref ref-type="table-fn" rid="tfn3-copd-9-805">&#x02020;</xref></td><td align="left" valign="top" rowspan="1" colspan="1">40.6&#x000b1;2.4<xref ref-type="table-fn" rid="tfn2-copd-9-805">**</xref></td><td align="left" valign="top" rowspan="1" colspan="1">51.6&#x000b1;1.4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;D<sub>LCO</sub>, % of predicted</td><td align="left" valign="top" rowspan="1" colspan="1">39.0&#x000b1;3.8<xref ref-type="table-fn" rid="tfn2-copd-9-805">**</xref></td><td align="left" valign="top" rowspan="1" colspan="1">38.6&#x000b1;6.2<xref ref-type="table-fn" rid="tfn2-copd-9-805">**</xref></td><td align="left" valign="top" rowspan="1" colspan="1">60.0&#x000b1;2.7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;D<sub>LCO</sub>/VA, % of predicted</td><td align="left" valign="top" rowspan="1" colspan="1">71.9&#x000b1;7.1<xref ref-type="table-fn" rid="tfn4-copd-9-805">&#x02020;&#x02020;</xref></td><td align="left" valign="top" rowspan="1" colspan="1">42.3&#x000b1;5.4<xref ref-type="table-fn" rid="tfn2-copd-9-805">**</xref></td><td align="left" valign="top" rowspan="1" colspan="1">71.9&#x000b1;3.4</td></tr></tbody></table><table-wrap-foot><fn><p><bold>Notes:</bold></p></fn><fn id="tfn1-copd-9-805"><label>*</label><p><italic>P</italic>&#x0003c;0.05 and</p></fn><fn id="tfn2-copd-9-805"><label>**</label><p><italic>P</italic>&#x0003c;0.01 versus COPD</p></fn><fn id="tfn3-copd-9-805"><label>&#x02020;</label><p><italic>P</italic>&#x0003c;0.05 and</p></fn><fn id="tfn4-copd-9-805"><label>&#x02020;&#x02020;</label><p><italic>P</italic>&#x0003c;0.01 versus CPFE OB<sup>+</sup>. Values are means &#x000b1; standard error of the mean.</p></fn><fn id="tfn5-copd-9-805"><p><bold>Abbreviations:</bold> BMI, body mass index; LAA, low attenuation area; HRCT, high-resolution computed tomography; FEV<sub>1</sub>, forced expiratory volume in 1 second; FVC, forced vital capacity; RV, residual volume; TLC, total lung capacity; D<sub>LCO</sub>, diffusing capacity of lung for carbon monoxide; D<sub>LCO</sub>/VA, D<sub>LCO</sub> corrected for alveolar volume; NA, not applicable; VC, vital capacity.</p></fn></table-wrap-foot></table-wrap></floats-group></article>